p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function

Zijun Y. Xu-Monette; Shanxiang Zhang; Xin Li; Ganiraju C. Manyam; Xiao-xiao Wang; Yi Xia; Carlo Visco; Alexandar Tzankov; Li Zhang; Santiago Montes-Moreno; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L. Richards; Eric D. Hsi; William W.L. Choi; J. Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J.M. Ferreri; Xiaoying Zhao; Michael B. Møller; Ben M. Parsons; Jane N. Winter; Miguel A. Piris; L. Jeffrey Medeiros; Ken H. Young

doi:doi:10.18632/aging.100898

← Back

Research Paper Volume 8, Issue 2 pp 345—365

p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function

Figure 3. Prognostic analysis of p63 expression in DLBCL. (a-b) p63 expression correlated with significantly better progression-free survival (PFS) but not overall survival (OS) in DLBCL. (c-d) p63 expression correlated with significantly better overall survival in DLBCL patients with IPI scores > 2 but not in DLBCL patients with IPI scores ≤ 2. (e-h) p63 expression correlated with significantly better PFS in ABC- but not GCB-DLBCL patients. (i-j) p63 expression was associated with trends towards better survival outcomes in GCB-DLBCL patients with IPI scores > 2. (k-l) p63 expression correlated with significantly better survival outcomes in ABC-DLBCL patients with IPI scores > 2.